This inventor holds 1 USPTO granted patent. Top assignee: Yissum Research Development Company of the Hebrew University of Jerusalem Ltd.. Active years: 2017.
Company Filing History:
Years Active: 2017
Title: Ariel Pribluda: Innovator in Cancer Treatment
Introduction
Ariel Pribluda is a notable inventor based in Beer-Sheva, Israel. He has made significant contributions to the field of cancer treatment through his innovative research and patented methods. His work focuses on developing techniques to target and kill cancerous cells, particularly those with mutations in the Adenomatous polyposis coli (APC) gene.
Latest Patents
Ariel Pribluda holds a patent for "Methods of killing cells and use of same in prevention and treatment of cancer." This patent describes a method for killing cells that have mutations in the APC gene. The method involves using an inhibitor of Casein kinase I (CKI), specifically CKI-alpha, CKI-delta, or CKI-epsilon, to effectively eliminate these mutated cells. This innovative approach has potential applications in treating various types of cancers. He has 1 patent to his name.
Career Highlights
Ariel Pribluda is associated with Yissum Research Development Company of the Hebrew University of Jerusalem Ltd. His work at this esteemed institution has allowed him to explore groundbreaking research in cancer therapies. His dedication to advancing medical science is evident in his innovative approaches to treatment.
Collaborations
Ariel has collaborated with notable colleagues, including Yinon Ben-Neriah and Ela Elyada. These partnerships have contributed to the development and refinement of his research in cancer treatment.
Conclusion
Ariel Pribluda is a pioneering inventor whose work in cancer treatment showcases the potential of innovative methods to combat serious diseases. His contributions to the field are significant and reflect a commitment to improving patient outcomes through scientific research.